Cost-effectiveness study of the MitraClip system for mitral regurgitation treatment in inoperable patients
The study aims to estimate the MitraClip system’s cost-effectiveness compared with optimal medical therapy in adult patients with inoperable mitral regurgitation and assess its impact on the budget of the Russian Federation health system.Materials and methods. The cost-effectiveness analysis of the...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
InterMedservice
2021-09-01
|
| Series: | Евразийский Кардиологический Журнал |
| Subjects: | |
| Online Access: | https://www.heartj.asia/jour/article/view/6280 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849402514252759040 |
|---|---|
| author | E. G. Fedina K. A. Perova T. S. Teptsova D. S. Shchurov |
| author_facet | E. G. Fedina K. A. Perova T. S. Teptsova D. S. Shchurov |
| author_sort | E. G. Fedina |
| collection | DOAJ |
| description | The study aims to estimate the MitraClip system’s cost-effectiveness compared with optimal medical therapy in adult patients with inoperable mitral regurgitation and assess its impact on the budget of the Russian Federation health system.Materials and methods. The cost-effectiveness analysis of the MitraClip system was carried out using the Markov model. The time horizon was three & five years. The budget impact analysis (BIA) model compared the costs of treating patients distributed across different management practices. Standard management practice included only optimal medical therapy. Expected management practice included different patient allocation between the MitraClip system and optimal medical therapy. The time horizon for the budget impact analysis was five years. Results. The incremental cost-effectiveness ratio (ICER) per additional quality-adjusted life-year (QALY) gained of the MitraClip system in comparison with optimal medical therapy was 6,271,657 rubles in three years and 3,451,342 rubles in five years. Based on the BIA results of the MitraClip system, its use would lead to an increase in costs by 12.6 billion rubles (+6.09%, minimal scenario), by 37.8 billion rubles (+18.28%, optimal scenario) or by 63 billion rubles (+30.47%, maximum scenario).Conclusion. As a result of the analysis performed, it was found that economic efficiency is noted with an increasing time horizon of up to five years. The obtained ICER values are comparable with the average values obtained in other foreign cost-effectiveness studies. The use of this technology will lead to an increase in direct medical costs by 6.09% over five years compared to the current management practice. In more comprehensive MitraClip system implementation (maximum scenario), direct medical costs will increase by 30.47% compared to the current management practice. |
| format | Article |
| id | doaj-art-bb31ea8b95f943b58cf993bc8cb64ff2 |
| institution | Kabale University |
| issn | 2225-1685 2305-0748 |
| language | Russian |
| publishDate | 2021-09-01 |
| publisher | InterMedservice |
| record_format | Article |
| series | Евразийский Кардиологический Журнал |
| spelling | doaj-art-bb31ea8b95f943b58cf993bc8cb64ff22025-08-20T03:37:31ZrusInterMedserviceЕвразийский Кардиологический Журнал2225-16852305-07482021-09-0103283510.38109/2225-1685-2021-3-28-356243Cost-effectiveness study of the MitraClip system for mitral regurgitation treatment in inoperable patientsE. G. Fedina0K. A. Perova1T. S. Teptsova2D. S. Shchurov3The Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian FederationThe Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian FederationThe Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian FederationThe Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian FederationThe study aims to estimate the MitraClip system’s cost-effectiveness compared with optimal medical therapy in adult patients with inoperable mitral regurgitation and assess its impact on the budget of the Russian Federation health system.Materials and methods. The cost-effectiveness analysis of the MitraClip system was carried out using the Markov model. The time horizon was three & five years. The budget impact analysis (BIA) model compared the costs of treating patients distributed across different management practices. Standard management practice included only optimal medical therapy. Expected management practice included different patient allocation between the MitraClip system and optimal medical therapy. The time horizon for the budget impact analysis was five years. Results. The incremental cost-effectiveness ratio (ICER) per additional quality-adjusted life-year (QALY) gained of the MitraClip system in comparison with optimal medical therapy was 6,271,657 rubles in three years and 3,451,342 rubles in five years. Based on the BIA results of the MitraClip system, its use would lead to an increase in costs by 12.6 billion rubles (+6.09%, minimal scenario), by 37.8 billion rubles (+18.28%, optimal scenario) or by 63 billion rubles (+30.47%, maximum scenario).Conclusion. As a result of the analysis performed, it was found that economic efficiency is noted with an increasing time horizon of up to five years. The obtained ICER values are comparable with the average values obtained in other foreign cost-effectiveness studies. The use of this technology will lead to an increase in direct medical costs by 6.09% over five years compared to the current management practice. In more comprehensive MitraClip system implementation (maximum scenario), direct medical costs will increase by 30.47% compared to the current management practice.https://www.heartj.asia/jour/article/view/6280systemmitral regurgitationcost-effectiveness studyincremental cost-effectiveness ratioicerquality-adjusted life yearsqalybudget impact analysis |
| spellingShingle | E. G. Fedina K. A. Perova T. S. Teptsova D. S. Shchurov Cost-effectiveness study of the MitraClip system for mitral regurgitation treatment in inoperable patients Евразийский Кардиологический Журнал system mitral regurgitation cost-effectiveness study incremental cost-effectiveness ratio icer quality-adjusted life years qaly budget impact analysis |
| title | Cost-effectiveness study of the MitraClip system for mitral regurgitation treatment in inoperable patients |
| title_full | Cost-effectiveness study of the MitraClip system for mitral regurgitation treatment in inoperable patients |
| title_fullStr | Cost-effectiveness study of the MitraClip system for mitral regurgitation treatment in inoperable patients |
| title_full_unstemmed | Cost-effectiveness study of the MitraClip system for mitral regurgitation treatment in inoperable patients |
| title_short | Cost-effectiveness study of the MitraClip system for mitral regurgitation treatment in inoperable patients |
| title_sort | cost effectiveness study of the mitraclip system for mitral regurgitation treatment in inoperable patients |
| topic | system mitral regurgitation cost-effectiveness study incremental cost-effectiveness ratio icer quality-adjusted life years qaly budget impact analysis |
| url | https://www.heartj.asia/jour/article/view/6280 |
| work_keys_str_mv | AT egfedina costeffectivenessstudyofthemitraclipsystemformitralregurgitationtreatmentininoperablepatients AT kaperova costeffectivenessstudyofthemitraclipsystemformitralregurgitationtreatmentininoperablepatients AT tsteptsova costeffectivenessstudyofthemitraclipsystemformitralregurgitationtreatmentininoperablepatients AT dsshchurov costeffectivenessstudyofthemitraclipsystemformitralregurgitationtreatmentininoperablepatients |